Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors

Oncologist

Volumn 22, Issue 10, 2017, Pages 1232-1237

  Judd, Julia ^a   Zibelman, Matthew ^b   Handorf, Elizabeth ^b   O’Neill, John ^b   Ramamurthy, Chethan ^b   Bentota, Sasini ^b   Doyle, Jamie ^b   Uzzo, Robert G ^b   Bauman, Jessica ^b   Borghaei, Hossein ^b   Plimack, Elizabeth R ^b   Mehra, Ranee ^b   Geynisman, Daniel M ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Checkpoint inhibitors; Immune related adverse events; Immunotherapy; Nivolumab; Pembrolizumab; Programmed cell death 1 inhibitors

Indexed keywords

CHECKPOINT KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; STEROID; ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVERSE EVENT; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RELATED ADVERSE EVENT; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; NON MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; MELANOMA;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES;

EID: 85034013471     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0133     Document Type: Article

References (24)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
2. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer. N Engl JMed 2015;373:1627-1639.
3. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
4. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed 2015;372:2018-2028.
5. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl JMed 2015;373:1803-1813.
6. Seiwert TY, Haddad RI, Gupta S et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Abstract presented at: ASCO Annual Meeting Proceedings; 2015; Chicago, IL.
7. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-1920.
8. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3543.
9. Hodi FS, Hwu WJ, Kefford R et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016;34:1510-1517.
10. Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
11. George S, Motzer RJ, Hammers HJ et al. Safety and efficacyof nivolumab in patientswithmetastatic renal cell carcinoma treated beyond progression: A subgroup analysis of a randomized clinical trial. JAMA Oncol 2016;2:1179-1186.
12. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTLassociated antigen-4 blockade. Clin Cancer Res 2007;13:6681-6688.
13. Teulings HE, Limpens J, Jansen SN et al. Vitiligolike depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic reviewandmeta-analysis. J Clin Oncol 2015;33:773-781.
14. Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015;151: 1206-1212.
15. Eigentler TK, Schlaak M, Hassel JC et al. Effectiveness and tolerability of ipilimumab: Experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J Immunother 2014;37:374-381.
16. Mian I, Yang M, Zhao H et al. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. J Clin Oncol 2016;34:3047a.
17. Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785-792.
18. Horvat TZ, Adel NG, Dang TO et al. Immunerelated adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab atMemorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193-3198.
19. Weber JS, Antonia SJ, Topalian SL et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 2015;33:9018a.
20. McDermott DF, Drake CG, Sznol M et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013-2020.
21. Prior LM, Harrold E, O’Leary CG et al. Toxicities in immunotherapy: Can they predict response? J Clin Oncol 2016;34:e14534a.
22. Freeman-Keller M, Kim Y, Cronin H et al. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886-894.
23. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression ofmetastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-830.
24. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 2016;54:139-148.